

Global Antibiotics Market - Distribution by Type of Drug Class (Aminoglycosides, Cephalosporins, Fluoroquinolones, Macrolides, Oxazolidinones, Penicillins, Sulphonamides, Tetracyclines and Other Drug Classes), Target Disease Indication (Bacterial Infections, Skin Infections, Gastrointestinal Infections, Hematological Infections, Nephrological Infections, Pulmonary Infections, Reproductive Tract Infections, Respiratory Tract Infections, Sexually Transmitted Diseases, Urinary Tract Infections and Other Bacterial Infections), Type of Therapy (Monotherapies and Combination Therapies), Route of Administration (Intravenous and Oral), Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World), and Drug-wise Sales: Industry Trends and Global Forecasts, 2023-2035

<https://marketpublishers.com/r/G8FD654A9153EN.html>

Date: April 2023

Pages: 175

Price: US\$ 4,799.00 (Single User License)

ID: G8FD654A9153EN

Abstracts

The global antibiotics market is expected to reach USD 36 billion in 2023 anticipated to grow at a CAGR of 1.2% during the forecast period 2023-2035.

Bacterial infections stand as a primary contributor to global mortality, accounting for one out of every eight deaths worldwide. This prevalence predominantly stems from the

escalation of resistant pathogenic bacteria against conventional treatments. The Centers for Disease Control and Prevention (CDC) notes that managing infections from six multi-drug resistant bacteria incurs an annual cost of over USD 4.6 billion in the United States alone. Antibiotics, sourced from biological or chemical origins, play a critical role in preventing and treating various bacterial infections. Recent advancements have led to the approval of diverse broad-spectrum and narrow-spectrum antibiotics designed to combat a range of bacterial diseases such as anthrax, botulism, cholera, gonorrhea, meningitis, pneumonia, tetanus, tuberculosis, and syphilis. Nevertheless, the development of antibiotic drugs encounters numerous challenges, including the emergence of multi-drug resistant bacteria, shortages—especially of penicillin and amoxicillin—and concerns regarding safety and efficacy. To address these challenges, stakeholders within the industry have actively engaged in research and development endeavors. Additionally, regulatory bodies such as the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and the United States Food and Drug Administration (USFDA) have initiated campaigns to promote appropriate antibiotic usage and extend support to the industry. Through the collaborative efforts of industry and non-industry entities, accompanied by escalating concerns surrounding antimicrobial resistance, the global antibiotics market is anticipated to experience significant growth in the projected period.

Report Coverage

The report examines the antibiotics market by categorizing it according to the type of drug class, target disease indication, type of therapy, route of administration and key geographical regions.

It conducts an analysis of factors—such as drivers, restraints, opportunities, and challenges—that impact the market's growth trajectory.

The report evaluates the potential advantages and obstacles within the market, providing insights into the competitive landscape for leading market players.

Revenue forecasts for market segments are projected across four major regions.

The executive summary segment provides an overview of the current global antibiotics market and its anticipated development in the medium to long term.

It offers an introduction to antibiotics, detailing their characteristics, advantages,

and classification based on chemical structure, mode of action, activity range, and source. This section encompasses historical perspectives, innovations, mechanisms of action, challenges, and future prospects.

A comprehensive analysis covers approval years, regions, antibiotic types, mechanisms of action, spectrum of activity, target bacteria, disease indications, source nature, therapy types, administration routes, dosage forms, patient populations, and developer details.

Similar to the generics analysis, a detailed examination focuses on branded antibiotics. Parameters considered include approval details, antibiotic types, mechanisms, spectrum, target bacteria, disease indications, therapy types, administration routes, dosage forms, patient populations, innovation types, and developer insights.

An in-depth evaluation of clinical-stage antibiotics includes development statuses, antibiotic types, mechanisms, spectra, target bacteria, disease indications, therapeutic areas, therapy types, administration routes, dosage forms, patient populations, special designations, and developer analyses.

Detailed profiles of significant players in antibiotic development encompass company overviews, key executives, financial data (if available), product portfolios, recent developments, future outlooks, strategic focus areas, and expert opinions.

Examination of partnerships between industry stakeholders since 2017, considering partnership types, partners, company sizes, active players, and regional distributions in the antibiotics market.

Exploration of completed and ongoing antibiotic-related clinical trials based on registration years, trial statuses, phases, patient populations, focus areas, sponsors, geographies, and active industry and non-industry players.

Insightful analysis of key opinion leaders involved in antibiotic-related clinical trials, focusing on their qualifications, affiliations, geographic locations, target disease indications, prominence based on proprietary and third-party criteria.

Elaboration on significant trends within the antibiotics industry, including drug pricing, outsourcing patterns, and the impact of COVID-19.

An analysis of recently approved antibiotics based on parameters such as dosing, efficacy, competition, innovation, price, prevalence, administration route, activity spectrum, therapy type, and target bacteria.

Key Market Companies

Bristol Myers Squibb

Daiichi Sankyo

GlaxoSmithKline

Melinta Therapeutics

Merck

Pfizer

Contents

1. EXECUTIVE SUMMARY

2. INTRODUCTION

- 2.1. Overview of Antibiotics
- 2.2. Characteristics of an Ideal Antibiotic
- 2.3. Advantages of Antibiotics
- 2.4. Classification of Antibiotics
- 2.5. History of Antibiotics
- 2.6. Innovations in Antibiotics
- 2.7. Mechanism of Action of Antibiotics
- 2.8. Challenges associated with the use of Antibiotics
- 2.9. Future Perspectives

3. MARKET LANDSCAPE: APPROVED ANTIBIOTIC GENERICS

- 3.1. Approved Antibiotic Generics: Overall Market Landscape
 - 3.1.1. Analysis by Year of Approval
 - 3.1.2. Analysis by Region(s) of Approval
 - 3.1.4. Analysis by Type of Antibiotic (based on Chemical Structure)
 - 3.1.3. Analysis by Type of Antibiotic (based on Drug Class)
 - 3.1.5. Analysis by Mechanism of Action
 - 3.1.6. Analysis by Spectrum of Activity
 - 3.1.7. Analysis by Type of Target Bacteria(s)
 - 3.1.8. Analysis by Target Bacterial Strain(s)
 - 3.1.9. Analysis by Target Disease Indication(s)
 - 3.1.10. Analysis by Nature of Source
 - 3.1.11. Analysis by Type of Therapy
 - 3.1.12. Analysis by Route(s) of Administration
 - 3.1.13. Analysis by Dosage Form(s)
 - 3.1.14. Analysis by Type of Patient Population (based on Age)
 - 3.1.15. Analysis by Type of Patient Population (based on Gender)
- 3.2. Approved Antibiotic Generics: Developer Landscape
 - 3.2.1. Analysis by Year of Establishment
 - 3.2.2. Analysis by Company Size
 - 3.2.3. Analysis by Location of Headquarters
 - 3.2.4. Most Active Players: Analysis by Number of Approved Generics

4. MARKET LANDSCAPE: APPROVED ANTIBIOTIC BRANDS

4.1. Approved Antibiotic Brands: Overall Market Landscape

- 4.1.1. Analysis by Year of Approval
- 4.1.2. Analysis by Region(s) of Approval
- 4.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
- 4.1.4. Analysis by Type of Antibiotic (based on Drug Class)
- 4.1.5. Analysis by Mechanism of Action
- 4.1.6. Analysis by Spectrum of Activity
- 4.1.7. Analysis by Type of Target Bacteria
- 4.1.8. Analysis by Target Bacterial Strain(s)
- 4.1.9. Analysis by Target Disease Indication(s)
- 4.1.10. Analysis by Nature of Source
- 4.1.11. Analysis by Type of Therapy
- 4.1.12. Analysis by Route(s) of Administration
- 4.1.13. Analysis by Dosage Form(s)
- 4.1.14. Analysis by Type of Patient Population (based on Age)
- 4.1.15. Analysis by Type of Patient Population (based on Gender)
- 4.1.16. Analysis by Type of Innovation

4.2. Approved Antibiotic Brands: Developer Landscape

- 4.2.1. Analysis by Year of Establishment
- 4.2.2. Analysis by Company Size
- 4.2.4. Analysis by Location of Headquarters
- 4.2.5. Most Active Players: Analysis by Number of Approved Brands

5. MARKET LANDSCAPE: CLINICAL-STAGE ANTIBIOTICS

5.1. Clinical -Stage Antibiotics: Overall Market Landscape

- 5.1.1. Analysis by Status of Development
- 5.1.2. Analysis by Stage of Development
- 5.1.3. Analysis by Type of Antibiotic (based on Chemical Structure)
- 5.1.4. Analysis by Type of Antibiotic (based on Drug Class)
- 5.1.5. Analysis by Mechanism of Action
- 5.1.6. Analysis by Spectrum of Activity
- 5.1.7. Analysis by Type of Target Bacteria(s)
- 5.1.8. Analysis by Target Bacterial Strain(s)
- 5.1.9. Analysis by Target Disease Indication(s)
- 5.1.10. Analysis by Therapeutic Area(s)

- 5.1.11. Analysis by Nature of Source
- 5.1.12. Analysis by Type of Therapy
- 5.1.13. Analysis by Route(s) of Administration
- 5.1.14. Analysis by Dosage Form(s)
- 5.1.15. Analysis by Dosage Strength
- 5.1.16. Analysis by Dosage Frequency
- 5.1.17. Analysis by Dosing Period
- 5.1.18. Analysis by Type of Patient Population (based on Age)
- 5.1.19. Analysis by Type of Patient Population (based on Gender)
- 5.1.20. Analysis by Special Designation Received
- 5.2. Clinical -Stage Antibiotics: Developer Landscape
 - 5.2.1. Analysis by Year of Establishment
 - 5.2.2. Analysis by Company Size
 - 5.2.3. Analysis by Location of Headquarters
 - 5.2.4. Most Active Players: Analysis by Number of Clinical-stage Antibiotics
 - 5.2.5. Most Active Players: Analysis by Number of Preclinical-stage Antibiotics

6. COMPANY PROFILES

- 6.1. Bristol-Myers Squibb
 - 6.1.1. Company Overview
 - 6.1.2. Key Executives
 - 6.1.3. Financial Information
 - 6.1.4. Product Portfolio
 - 6.1.5. Recent Developments
 - 6.1.6. Key Strategies
 - 6.1.7. Key Focus Areas
 - 6.1.8. Expert Opinion
- 6.2. Daiichi Sankyo
 - 6.2.1. Company Overview
 - 6.2.2. Key Executives
 - 6.2.3. Financial Information
 - 6.2.4. Product Portfolio
 - 6.2.5. Recent Developments
 - 6.2.6. Key Strategies
 - 6.2.7. Key Focus Areas
 - 6.2.8. Expert Opinion
- 6.3. GlaxoSmithKline
 - 6.3.1. Company Overview

- 6.3.2. Key Executives
- 6.3.3. Financial Information
- 6.3.4. Product Portfolio
- 6.3.5. Recent Developments
- 6.3.6. Key Strategies
- 6.3.7. Key Focus Areas
- 6.3.8. Expert Opinion
- 6.4. Melinta Therapeutics
 - 6.4.1. Company Overview
 - 6.4.2. Key Executives
 - 6.4.3. Financial Information
 - 6.4.4. Product Portfolio
 - 6.4.5. Recent Developments
 - 6.4.6. Key Strategies
 - 6.4.7. Key Focus Areas
 - 6.4.8. Expert Opinion
- 6.5. Merck
 - 6.5.1. Company Overview
 - 6.5.2. Key Executives
 - 6.5.3. Financial Information
 - 6.5.4. Product Portfolio
 - 6.5.5. Recent Developments
 - 6.5.6. Key Strategies
 - 6.5.7. Key Focus Areas
 - 6.5.8. Expert Opinion
- 6.6. Pfizer
 - 6.6.1. Company Overview
 - 6.6.2. Key Executives
 - 6.6.3. Financial Information
 - 6.6.4. Product Portfolio
 - 6.6.5. Recent Developments
 - 6.6.6. Key Strategies
 - 6.6.7. Key Focus Areas
 - 6.6.8. Expert Opinion
- 6.7. Concluding Remarks

7. PARTNERSHIPS AND COLLABORATIONS ANALYSIS

7.1. Partnership Models

7.2. Antibiotics: List of Partnerships and Collaborations

- 7.2.1. Analysis by Year of Partnership
- 7.2.2. Analysis by Type of Partnership
- 7.2.3. Analysis by Type of Partner
- 7.2.4. Analysis by Company Size
- 7.2.5. Local and International Agreements
- 7.2.6. Intracontinental and Intercontinental Agreements
- 7.2.7. Most Active Players: Analysis by Number of Partnerships
- 7.2.8. Concluding Remarks

8. CLINICAL TRIAL ANALYSIS

8.1. Analysis Methodology and Key Parameters

8.2. Antibiotics: Clinical Trial Analysis

- 8.2.1. Analysis by Trial Registration Year
- 8.2.2. Analysis by Trial Status
- 8.2.3. Analysis by Trial Phase
- 8.2.4. Analysis by Type of Patient Population (based on Gender)
- 8.2.5. Word Cloud Analysis: Key Focus Areas
- 8.2.6. Analysis by Type of Sponsor
- 8.2.7. Analysis by Geography
- 8.2.8. Most Active Industry Players: Analysis by Number of Trials
- 8.2.9. Most Active Non-Industry Players: Analysis by Number of Trials

9. KEY OPINION LEADERS

9.1. Assumptions and Key Parameters

9.2. Methodology

9.3. Antibiotics: Key Opinion Leaders (KOLs)

- 9.3.1. Analysis by Type of KOL
- 9.3.2. Analysis by Qualification
- 9.3.3. Analysis by Type of Organization
- 9.3.4. Analysis by Affiliated Organization
- 9.3.5. Analysis by Geographical Location of KOLs
- 9.3.6. Analysis by Target Disease Indication(s)
- 9.3.7. Most Prominent KOLs: Peer Group 1 (Principal Investigators)
- 9.3.8. Most Prominent KOLs: Peer Group 2 (Other Types of Investigators)
- 9.3.9. Most Prominent KOLs: Analysis by RA score
- 9.3.10. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

9.3.11. Concluding Remarks

10. KEY TRENDS IN ANTIBIOTICS INDUSTRY

10.1. Antibiotics Industry: Drug-Pricing Analysis

10.2. Antibiotics Industry: Outsourcing Trends

10.3. Antibiotics Industry: Impact of COVID-19

11. APPROVED ANTIBIOTICS: SUCCESS PROTOCOL ANALYSIS

11.1. Chapter Overview

11.2. Methodology

11.3. Success Protocol Analysis of Recently Approved Antibiotic Brands

11.3.1. Dovprela (TB Alliance)

11.3.1.1. Drug Overview

11.3.1.2. Success Protocol Analysis

11.3.2. Fetroja (Shionogi)

11.3.2.1. Drug Overview

11.3.2.2. Success Protocol Analysis

11.3.4. Kimyrsa (Melinta Therapeutics)

11.3.4.1. Drug Overview

11.3.4.2. Success Protocol Analysis

11.3.5 Recarbrio (Merck)

11.3.5.1. Drug Overview

11.3.5.2. Success Protocol Analysis

11.3.6. Quofenix (Menarini)

11.3.6.1. Drug Overview

11.3.6.2. Success Protocol Analysis

11.3.9 Xenleta (Nabriva Therapeutics)

11.3.9.1. Drug Overview

11.3.9.2. Success Protocol Analysis

11.4. Concluding Remarks

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

12.1. Chapter Overview

12.2. Key Assumptions and Methodology

12.3. Global Antibiotics Market, 2023-2035

12.3.1. Antibiotics Market: Distribution by Type of Drug Class, 2023 and 2035

- 12.3.1.1. Antibiotics Market for Aminoglycosides, 2023-2035
- 12.3.1.2. Antibiotics Market for Cephalosporins, 2023-2035
- 12.3.1.3. Antibiotics Market for Fluoroquinolones, 2023-2035
- 12.3.1.4. Antibiotics Market for Macrolides, 2023-2035
- 12.3.1.5. Antibiotics Market for Oxazolidinones, 2023-2035
- 12.3.1.6. Antibiotics Market for Penicillins, 2023-2035
- 12.3.1.7. Antibiotics Market for Sulphonamides, 2023-2035
- 12.3.1.8. Antibiotics Market for Tetracyclines, 2023-2035
- 12.3.1.9. Antibiotics Market for Other Classes, 2023-2035
- 12.3.2. Antibiotics Market: Distribution by Target Disease Indication, 2023 and 2035
 - 12.3.2.1. Antibiotics Market for Bacterial Infections, 2023-2035
 - 12.3.2.2. Antibiotics Market for Dermatological/ Skin Infections, 2023-2035
 - 12.3.2.3. Antibiotics Market for Gastrointestinal Infections, 2023-2035
 - 12.3.2.4. Antibiotics Market for Hematological Infections, 2023-2035
 - 12.3.2.5. Antibiotics Market for Nephrological Infections, 2023-2035
 - 12.3.2.6. Antibiotics Market for Pulmonary Infections, 2023-2035
 - 12.3.2.7. Antibiotics Market for Reproductive Tract Infections, 2023-2035
 - 12.3.2.8. Antibiotics Market for Respiratory Tract Infections, 2023-2035
 - 12.3.2.9. Antibiotics Market for Sexually Transmitted Diseases, 2023-2035
 - 12.3.2.10. Antibiotics Market for Urinary Tract Infections, 2023-2035
 - 12.3.2.11. Antibiotics Market for Other Bacterial Infections, 2023-2035
- 12.3.3. Antibiotics Market: Distribution by Type of Therapy, 2023 and 2035
 - 12.3.3.1. Antibiotics Market for Monotherapies, 2023-2035
 - 12.3.3.2. Antibiotics Market for Combination Therapies, 2023-2035
- 12.3.4. Antibiotics Market: Distribution by Route of Administration, 2023 and 2035
 - 12.3.4.1. Antibiotics Market for Intravenous Therapies, 2023-2035
 - 12.3.4.2. Antibiotics Market for Oral Therapies, 2023-2035
- 12.3.5. Antibiotics Market: Distribution by Geography, 2023 and 2035
 - 12.3.5.1. Antibiotics Market in North America, 2023-2035
 - 12.3.5.2. Antibiotics Market in Europe, 2023-2035
 - 12.3.5.2. Antibiotics Market in Asia-Pacific, 2023-2035
 - 12.3.5.3. Antibiotics Market in Rest of the World, 2023-2035
- 12.3.6. Sales Forecast: Approved Antibiotics
 - 12.3.6.1. Aemcolo®: Sales Forecast, 2023-2035
 - 12.3.6.2. Arikayce®: Sales Forecast, 2023-2035
 - 12.3.6.3. Baxdela™: Sales Forecast, 2023-2035
 - 12.3.6.4. Dalacin C: Sales Forecast, 2023-2035
 - 12.3.6.5. Dovprela®: Sales Forecast, 2023-2035
 - 12.3.6.6. Emrok: Sales Forecast, 2023-2035

- 12.3.6.7. Emrok-O: Sales Forecast, 2023-2035
- 12.3.6.8. Fetroja®: Sales Forecast, 2023-2035
- 12.3.6.9. Kimyrsa™: Sales Forecast, 2023-2035
- 12.3.6.10. Lasvic®: Sales Forecast, 2023-2035
- 12.3.6.11. Nuzyra®: Sales Forecast, 2023-2035
- 12.3.6.12. Orbactiv™/Tenkasi: Sales Forecast, 2023-2035
- 12.3.6.13. Ozanex™: Sales Forecast, 2023-2035
- 12.3.6.14. Quofenix: Sales Forecast, 2023-2035
- 12.3.6.15. Recarbrio™: Sales Forecast, 2023-2035
- 12.3.6.16. Seysara™: Sales Forecast, 2023-2035
- 12.3.6.17. Solosec®: Sales Forecast, 2023-2035
- 12.3.6.18. Vabomere™: Sales Forecast, 2023-2035
- 12.3.6.19. Xenleta™: Sales Forecast, 2023-2035
- 12.3.6.20. XEPI™: Sales Forecast, 2023-2035
- 12.3.6.21. Xerava™: Sales Forecast, 2023-2035
- 12.3.6.22. Xydalba®: Sales Forecast, 2023-2035
- 12.3.6.23. Youxitai: Sales Forecast, 2023-2035
- 12.3.6.24. Zemdri™: Sales Forecast, 2023-2035
- 12.3.6.25. Zerbaxa®: Sales Forecast, 2023-2035
- 12.3.6.26. Zyvoxam®: Sales Forecast, 2023-2035
- 12.3.7. Sales Forecast: Clinical-stage Antibiotics
 - 12.3.7.1. Cefepime-Taniborbactam: Sales Forecast, 2023-2035
 - 12.3.7.2. CONTEPO™: Sales Forecast, 2023-2035
 - 12.3.7.3. Gepotidacin (GSK2140944): Sales Forecast, 2023-2035
 - 12.3.7.4. MBK-01: Sales Forecast, 2023-2035
 - 12.3.7.5. MRX-4 (Contezolid Acefosamil): Sales Forecast, 2023-2035
 - 12.3.7.6. Nafithromycin (WCK 4873): Sales Forecast, 2023-2035
 - 12.3.7.7. RHB-104 (Rifabutin/clarithromycin/clofazimine): Sales Forecast, 2023-2035
 - 12.3.7.8. RHB-204 (clarithromycin, rifabutin, and clofazimin): Sales Forecast, 2023-2035
 - 12.3.7.9. Ridinilazole (SMT 19969): Sales Forecast, 2023-2035
 - 12.3.7.10. Sulopenem- etzadroxil- probenecid: Sales Forecast, 2023-2035
 - 12.3.7.11. Tebipenem HBr: Sales Forecast, 2023-2035
 - 12.3.7.12. WCK 4282 (Cefepime-Tazobactam): Sales Forecast, 2023-2035
 - 12.3.7.13. WCK 5222 (cefepime + zidebactam): Sales Forecast, 2023-2035
 - 12.3.7.14. XNW4107 (Funobactam): Sales Forecast, 2023-2035
 - 12.3.7.15. Zabofloxacin: Sales Forecast, 2023-2035
 - 12.3.7.16. Zoliflodacin (ETX0914): Sales Forecast, 2023-2035

13. APPENDIX I: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

I would like to order

Product name: Global Antibiotics Market - Distribution by Type of Drug Class (Aminoglycosides, Cephalosporins, Fluoroquinolones, Macrolides, Oxazolidinones, Penicillins, Sulphonamides, Tetracyclines and Other Drug Classes), Target Disease Indication (Bacterial Infections, Skin Infections, Gastrointestinal Infections, Hematological Infections, Nephrological Infections, Pulmonary Infections, Reproductive Tract Infections, Respiratory Tract Infections, Sexually Transmitted Diseases, Urinary Tract Infections and Other Bacterial Infections), Type of Therapy (Monotherapies and Combination Therapies), Route of Administration (Intravenous and Oral), Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World), and Drug-wise Sales: Industry Trends and Global Forecasts, 2023-2035

Product link: <https://marketpublishers.com/r/G8FD654A9153EN.html>

Price: US\$ 4,799.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8FD654A9153EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970